## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%); PEG 1.61 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($36.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Voya Investment Management LLC Sells 557,418 Shares of Centene Corporation $CNC**
- Source: MarketBeat | 20251222T130213 | Neutral | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in Centene Corporation (NYSE:CNC) by selling 557,418 shares, a 42.2% decrease, during the third quarter. Despite this, other major institutional investors like Vanguard Group Inc., Norges Bank, and State Street Corp. either increased or acquired new positions in Centene. Analysts maintain a "Hold" rating on Centene with a consensus price target of $38.44, following its recent earnings beat.

**2. Board of the Pension Protection Fund Invests $1 Million in Centene Corporation $CNC**
- Source: MarketBeat | 20251221T040738 | Somewhat-Bullish | Relevance: 100%
- The Board of the Pension Protection Fund has invested $1.003 million in Centene Corporation (NYSE:CNC), purchasing 28,100 shares in the third quarter. Centene exceeded earnings expectations with $0.50 EPS against a -$0.21 consensus and reported $49.69 billion in revenue, an 18.2% year-over-year increase. The stock, currently trading around $39.02, has a "Hold" consensus rating from analysts.

**3. eHealth's Guidance Update: Here's What a Strong AEP Signals**
- Source: TradingView â€” Track All Markets | 20251223T140836 | Somewhat-Bullish | Relevance: 62%
- eHealth, Inc. (EHTH) has raised its fiscal year 2025 financial outlook after a strong Annual Enrollment Period, particularly in its Medicare business, projecting higher revenue and significantly increased GAAP net income and adjusted EBITDA. This positive revision is attributed to stable enrollment, a shift to high-quality direct channels, and the effective use of AI tools, signaling improved profitability and operational discipline. The company's stock has outperformed the market, and despite a low price-to-sales ratio, it carries a Zacks Rank #3 (Hold).

**4. OIG Audit of Humana Medicare Advantage Contract Underscores Continued Scrutiny of High-Risk Diagnoses and Ongoing Disputes Over Audit Methodology**
- Source: WilmerHale | 20251223T175358 | Neutral | Relevance: 61%
- The OIG audit of a Humana Medicare Advantage contract highlights ongoing regulatory focus on "high-risk" diagnosis codes, leading to disputes over audit methodology, particularly regarding extrapolation and credit for underpayments. The article discusses Humana's objections to the audit findings and the broader implications for Medicare Advantage Organizations (MAOs) amidst evolving litigation and regulatory scrutiny. MAOs are advised to diligently preserve objections during audits to facilitate potential future litigation.

**5. Trump administration ups payer price transparency requirements**
- Source: TechTarget | 20251223T152105 | Somewhat-Bullish | Relevance: 61%
- The Trump administration has proposed significant updates to the Transparency in Coverage (TiC) rule, aiming to improve healthcare price transparency. These updates, developed by CMS, the Department of Labor, and the Department of the Treasury, seek to address issues like data inaccessibility and ambiguity in current compliance. The changes include reformatting data files, requiring change logs, and strengthening price comparison tools, though no new requirements for prescription drug price transparency were included.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 8.5% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.61 elevated, pricing in significant growth expectations. Forward P/E 13.7x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.5B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.61 |
| Forward P/E | 13.7 |
| Current P/E | 19.6 |
| YoY Growth | 43.0% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.2% to -1.3% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 56. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.32% (CS: 44) | Neutral |
| RSI_14 | 56.2 | Neutral |
| MACD Histogram | -0.07 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.066x | Above |
| vs SMA200 | 0.915x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $39.59
- **Stop Loss:** $36.85 (6.9% risk)
- **Target:** $42.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 437
- **Position Value:** $17,300.83
- **Portfolio %:** 17.30%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*